Metalore Resources Limited (TSXV:MET)

CTI BioPharma Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	0.55	0.44	0.48	1.43	0.56
Short-Term Investments	4.59	4.64	4.65	3.24	4.08
Cash & Short-Term Investments	5.14	5.09	5.13	4.66	4.64
Cash Growth	1.04%	-0.83%	9.96%	0.41%	693.97%
Receivables	0.84	0.03	0.04	0.11	0.06
Inventory	0.03	0.03	0.03	0.03	0.02
Prepaid Expenses	0.02	0.05	0.04	0.04	0.04
Total Current Assets	6.02	5.2	5.25	4.84	4.77
Property, Plant & Equipment	2.35	2.08	4.14	6.7	4.38
Total Assets	8.37	7.28	9.39	11.54	9.15
Accounts Payable	0.16	0.07	0.07	0.07	0.1
Current Income Taxes Payable	0.1	-	0.07	0.01	-
Total Current Liabilities	0.26	0.07	0.14	0.08	0.1
Long-Term Deferred Tax Liabilities	-	-	0.05	0.86	0.24
Other Long-Term Liabilities	0.75	0.94	2.01	1.58	1.54
Total Liabilities	1.01	1.01	2.2	2.52	1.89
Common Stock	2.47	2.47	2.47	2.47	2.47
Additional Paid-In Capital	0.15	0.15	0.15	0.15	0.15
Retained Earnings	4.69	3.59	4.68	6.42	4.71
Comprehensive Income & Other	0.05	0.05	-0.12	-0.02	-0.07
Shareholders' Equity	7.36	6.27	7.19	9.01	7.26
Total Liabilities & Equity	8.37	7.28	9.39	11.54	9.15
Net Cash (Debt)	5.14	5.09	5.13	4.66	4.64
Net Cash Growth	1.04%	-0.83%	9.96%	0.41%	693.97%
Net Cash Per Share	2.89	2.86	2.89	2.63	2.62
Filing Date Shares Outstanding	1.78	1.78	1.78	1.78	1.78
Total Common Shares Outstanding	1.78	1.78	1.78	1.78	1.78
Working Capital	5.76	5.13	5.11	4.76	4.66
Book Value Per Share	4.15	3.53	4.05	5.08	4.09
Tangible Book Value	7.36	6.27	7.19	9.01	7.26
Tangible Book Value Per Share	4.15	3.53	4.05	5.08	4.09
Land	0.13	0.13	0.13	0.13	0.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.